certepetide + durvalumab + cisplatin + gemcitabine

This is a **combination regimen** of certepetide (a novel, investigational cyclic peptide that selectively targets αv integrins and neuropilin-1 on tumor endothelium/cells, facilitating tumor-specific uptake of co-administered anti-cancer agents and modulating the tumor microenvironment), durvalumab (a human IgG1k monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80, restoring T-cell antitumor activity), cisplatin (a platinum-based chemotherapy that causes DNA crosslinking and apoptosis in cancer cells), and gemcitabine (a nucleoside analog chemotherapy that induces apoptosis by inhibiting DNA synthesis). The regimen is investigated as a strategy for enhanced tumor targeting, immune modulation, and cytotoxicity, especially in solid tumors such as pancreatic ductal adenocarcinoma and cholangiocarcinoma[1][2][3][4][5][6].

Brand names

No unique brand names identified for this specific combination

Other names

certepetide + durvalumab + cisplatin + gemcitabine